College of Pharmacy, Faculty of Health, Dalhousie University, 5968 College Street, PO Box 15000, B3H 4R2, Halifax, NS, Canada.
Division of Geriatric Medicine, Department of Medicine, Dalhousie University, Halifax, Canada.
BMC Geriatr. 2023 Oct 20;23(1):683. doi: 10.1186/s12877-023-04353-8.
Older adults living with dementia may express challenging responsive behaviours. One management strategy is pharmacologic treatment though these options often have limited benefit, which may lead to multiple treatments being prescribed.
The aim of the present study was to describe psychoactive medication polypharmacy and explore factors associated with psychoactive polypharmacy in a cohort of older adults living with dementia in Nova Scotia, Canada, including a gender-stratified analysis. This was a retrospective cohort study of those aged 65 years or older with a recorded diagnosis of dementia between 2005 and 2015. Medication dispensation data was collected from April 1, 2010, or dementia diagnosis (cohort entry) to either death or March 31, 2015 (cohort exit). Psychoactive medication claims were captured. Psychoactive medication polypharmacy was defined as presence of three or more psychoactive prescription medications dispensed to one subject and overlapping for more than 30 days. Psychoactive polypharmacy episodes were described in duration, quantity, and implicated medications. Regression analysis examined factors associated with experience and frequency of psychoactive polypharmacy. All analysis were stratified by gender.
The cohort included 15,819 adults living with dementia (mean age 80.7 years; 70.0% female), with 99.4% (n = 15,728) receiving at least one psychoactive medication over the period of follow-up. Psychoactive polypharmacy was present in 19.3% of the cohort. The gender specific logistic regressions demonstrated that for both men and women a younger age was associated with an increased risk of psychoactive polypharmacy (women: OR 0.97, 95%CI[0.96, 0.98], men: OR 0.96, 95%CI[0.95, 0.97]). Men were less likely to experience psychoactive polypharmacy if their location of residence was urban (OR 0.86, 95%CI[0.74, 0.99]). There was no significant association between location of residence (urban or rural) and psychoactive polypharmacy for women living with dementia. Antidepressants were the most dispensed medication class, while quetiapine was the most dispensed medication.
This study suggests that of adults living with dementia those of younger ages were more likely to experience psychoactive polypharmacy and that men living with dementia in rural locations may benefit from increased access to non-pharmacological options for dementia management.
患有痴呆症的老年人可能会表现出具有挑战性的反应行为。一种管理策略是药物治疗,尽管这些选择通常益处有限,这可能导致开出多种治疗药物。
本研究的目的是描述患有痴呆症的老年人的精神药物多药治疗,并探讨与加拿大新斯科舍省一组患有痴呆症的老年人的精神药物多药治疗相关的因素,包括性别分层分析。这是一项回顾性队列研究,纳入了 2005 年至 2015 年间记录有痴呆症诊断的年龄在 65 岁或以上的患者。从 2010 年 4 月 1 日或痴呆症诊断(队列入组)至死亡或 2015 年 3 月 31 日(队列出组)收集药物配给数据。捕获精神药物处方。精神药物多药治疗定义为向一名受试者开具三种或三种以上精神药物处方,且重叠时间超过 30 天。描述了精神药物多药治疗的持续时间、数量和涉及的药物。回归分析检查了与精神药物多药治疗经历和频率相关的因素。所有分析均按性别分层。
该队列包括 15819 名患有痴呆症的成年人(平均年龄 80.7 岁;70.0%为女性),在随访期间,99.4%(n=15728)至少服用过一种精神药物。该队列中有 19.3%的人存在精神药物多药治疗。性别特异性逻辑回归表明,对于男性和女性,年龄较小与精神药物多药治疗的风险增加相关(女性:OR 0.97,95%CI[0.96,0.98];男性:OR 0.96,95%CI[0.95,0.97])。如果居住地点为城市,男性患精神药物多药治疗的可能性较低(OR 0.86,95%CI[0.74,0.99])。对于患有痴呆症的女性,居住地(城市或农村)与精神药物多药治疗之间没有显著关联。抗抑郁药是配药最多的药物类别,而喹硫平是配药最多的药物。
本研究表明,在患有痴呆症的成年人中,年龄较小的成年人更有可能经历精神药物多药治疗,而居住在农村地区的患有痴呆症的男性可能受益于增加非药物治疗选择来管理痴呆症。